Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

OrbiMed to Raise $450 Million for Third Asia Life Science Fund

publication date: Mar 2, 2017
OrbiMed filed with the SEC to raise $450 million for its third Asia-focused fund, OrbiMed Asia Partners III L.P. Originally formed in 1989, OrbiMed maintains a strictly life science focus globally, with $13 billion under management and investments from early stage to private and public equity. The company opened offices in Shanghai and Mumbai in 2007 and now runs over $500 million in investments from its first two Asia funds. OrbiMed's Asia II partnership closed in 2014 with $325 million. The company says it considers investments in all sectors of life science, from biopharmaceuticals to medical devices, diagnostics and healthcare services. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital